Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 5OTHER_GOV 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 50Ovarian Neoplasms 43Lung Neoplasms 41Fallopian Tube Neoplasms 29Carcinoma, Ovarian Epithelial 28Breast Neoplasms 22Neuroblastoma 18Adenocarcinoma of Lung 17Central Nervous System Neoplasms 16Brenner Tumor 12Endometrial Neoplasms 9Adenocarcinoma, Bronchiolo-Alveolar 9Testicular Neoplasms 8Squamous Cell Carcinoma of Head and Neck 8Astrocytoma 8Unspecified Adult Solid Tumor, Protocol Specific 7Triple Negative Breast Neoplasms 7Oligodendroglioma 7Lymphoma, Large B-Cell, Diffuse 7Brain Neoplasms 7Head and Neck Neoplasms 6Teratoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Melanoma 5Medulloblastoma 5Leukemia, Myeloid, Acute 5Gliosarcoma 5Glioblastoma 5Thrombocythemia, Essential 4Testicular Germ Cell Tumor 4

Interventions

durvalumab 1Pemetrexed 1Paclitaxel 1Gemcitabine 1Cisplatin 1Carboplatin 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Pathologic Complete Response × Carboplatin × Clear all
NCT06694454 2026-06-04

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
60 enrolled
Thoracic

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡